Sandra Porcile Rojas-Caro
Director/Board Member at RIPLEY CORP S.A.
Sandra Porcile Rojas-Caro active positions
| Companies | Position | Start | End |
|---|---|---|---|
| RIPLEY CORP S.A. | Director/Board Member | 2019-12-31 | - |
| Independent Dir/Board Member | 2019-12-31 | - |
Career history of Sandra Porcile Rojas-Caro
Former positions of Sandra Porcile Rojas-Caro
| Companies | Position | Start | End |
|---|---|---|---|
| NEUBASE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-05-23 | 2022-10-27 |
| GEMI THER | Chief Tech/Sci/R&D Officer | - | - |
| SPYRE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2016-05-15 | - |
| SYNAGEVA BIOPHARMA CORP | Chief Tech/Sci/R&D Officer | 2012-12-31 | - |
Training of Sandra Porcile Rojas-Caro
| Pontificia Universidad Católica de Chile | Doctorate Degree |
Statistics
International
| United States | 5 |
| Chile | 3 |
Operational
| Chief Tech/Sci/R&D Officer | 4 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
| Retail Trade | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| NEUBASE THERAPEUTICS, INC. | Health Technology |
| RIPLEY CORP S.A. | Retail Trade |
| Private companies | 2 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
